NASDAQ:STIM Neuronetics (STIM) Stock Price, News & Analysis $1.18 0.00 (0.00%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$1.20 +0.02 (+1.69%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Neuronetics Stock (NASDAQ:STIM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neuronetics alerts:Sign Up Key Stats Today's Range$1.12▼$1.2350-Day Range$1.18▼$2.1752-Week Range$0.80▼$4.85Volume3.22 million shsAverage Volume2.73 million shsMarket Capitalization$82.12 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company Overview Neuronetics, Inc. is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy. Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation. The company’s platform is designed for use in outpatient clinics, hospitals and psychiatry practices across the United States. Neuronetics maintains a specialized field sales force and collaborates with key channel partners to support physician training, patient education and therapy delivery. In addition to its commercial activities, the company continues to explore new indications and protocol optimizations to expand its therapeutic offerings. Guided by a leadership team with deep experience in medical devices and neuroscience, Neuronetics strives to improve patient outcomes through research, regulatory engagement and post-market data collection. The company’s ongoing efforts include refining device features, enhancing treatment compliance and evaluating the use of its technology in other neuropsychiatric conditions. Neuronetics is publicly traded on the Nasdaq under the symbol STIM.AI Generated. May Contain Errors. Read More Neuronetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreSTIM MarketRank™: Neuronetics scored higher than 67% of companies evaluated by MarketBeat, and ranked 268th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingNeuronetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialNeuronetics has a consensus price target of $3.00, representing about 154.2% upside from its current price of $1.18.Amount of Analyst CoverageNeuronetics has only been the subject of 1 research reports in the past 90 days.Read more about Neuronetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($0.46) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 4.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neuronetics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.43% of the float of Neuronetics has been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 6.21.Change versus previous monthShort interest in Neuronetics has recently decreased by 4.06%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.30 News SentimentNeuronetics has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Neuronetics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows2 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.8 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $2,946,378.00 in company stock, which represents 3.5881% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have bought 2,424.44% more of their company's stock than they have sold. Specifically, they have bought $3,067,906.00 in company stock and sold $121,528.00 in company stock.Percentage Held by Insiders8.40% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neuronetics' insider trading history. Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STIM Stock News HeadlinesNeuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS TreatmentMay 14, 2026 | globenewswire.comJorey Chernett Purchases 475,000 Shares of Neuronetics (NASDAQ:STIM) StockMay 14, 2026 | insidertrades.comI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement. | Porter & Company (Ad)Neuronetics (STIM) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comNeuronetics, Inc. (STIM) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comNeuronetics Reports First Quarter 2026 Financial and Operating ResultsMay 5, 2026 | globenewswire.comHow The Neuronetics (STIM) Investment Story Is Evolving With A Reset Price TargetMay 2, 2026 | finance.yahoo.comInsider Buying: Neuronetics (NASDAQ:STIM) Major Shareholder Purchases 100,000 Shares of StockApril 23, 2026 | insidertrades.comSee More Headlines STIM Stock Analysis - Frequently Asked Questions How have STIM shares performed this year? Neuronetics' stock was trading at $1.38 at the start of the year. Since then, STIM shares have decreased by 14.5% and is now trading at $1.18. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) announced its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. The company earned $34.45 million during the quarter, compared to analyst estimates of $34.17 million. Neuronetics had a negative trailing twelve-month return on equity of 139.83% and a negative net margin of 24.48%. Read the conference call transcript. When did Neuronetics IPO? Neuronetics (STIM) raised $82 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,500,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. Who are Neuronetics' major shareholders? Neuronetics' top institutional shareholders include FourWorld Capital Management LLC (2.14%), AdvisorShares Investments LLC (0.89%), Citizens Financial Group Inc. RI (0.16%) and ADAR1 Capital Management LLC (0.14%). Insiders that own company stock include Keith J Sullivan, William Andrew Macan, Steven Pfanstiel, Robert Cascella, Stephen Furlong and Glenn P Muir. View institutional ownership trends. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), GE Aerospace (GE), Intel (INTC), Bank of America (BAC) and Nokia (NOK). Company Calendar Last Earnings5/05/2026Today5/19/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 STIM's financial health is in the Red zone, according to TradeSmith. STIM has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:STIM CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees180Year Founded2003Price Target and Rating Average Price Target for Neuronetics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+154.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39 million Net Margins-24.48% Pretax Margin-24.55% Return on Equity-139.83% Return on Assets-27.13% Debt Debt-to-Equity Ratio3.59 Current Ratio1.67 Quick Ratio1.50 Sales & Book Value Annual Sales$149.16 million Price / Sales0.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book4.72Miscellaneous Outstanding Shares69,590,000Free Float63,743,000Market Cap$82.12 million OptionableOptionable Beta1.13 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:STIM) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
